Complete report details @https://www.wiseguyreports.com/reports/649777-hemorrhagic-shock-pipeline-review-h2-2016
Summary
‘Hemorrhagic Shock -
Pipeline Review, H2 2016’, provides an overview of the Hemorrhagic Shock
pipeline landscape.
The report provides comprehensive information on the
therapeutics under development for Hemorrhagic Shock, complete with analysis by
stage of development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The report also covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases. Additionally, the
report provides an overview of key players involved in therapeutic development
for Hemorrhagic Shock and features dormant and discontinued projects.
Report features investigational drugs from across globe
covering over 20 therapy areas and nearly 3,000 indications. The report is
built using data and information sourced from proprietary databases,
company/university websites, clinical trial registries, conferences, SEC
filings, investor presentations and featured press releases from
company/university sites and industry-specific third party sources. Drug
profiles featured in the report undergoes periodic review following a stringent
set of processes to ensure that all the profiles are updated with the latest
set of information. Additionally, various dynamic tracking processes ensure
that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging
players in the market and their portfolios, enhances decision making
capabilities and helps to create effective counter strategies to gain
competitive advantage.
Make an enquiry before buying this Report @
https://www.wiseguyreports.com/reports/649777-hemorrhagic-shock-pipeline-review-h2-2016
Scope
- The report provides a snapshot of the global therapeutic
landscape of Hemorrhagic Shock
- The report reviews pipeline therapeutics for Hemorrhagic Shock by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Hemorrhagic Shock therapeutics and enlists all their major and minor projects
- The report assesses Hemorrhagic Shock therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Hemorrhagic Shock
- The report reviews pipeline therapeutics for Hemorrhagic Shock by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Hemorrhagic Shock therapeutics and enlists all their major and minor projects
- The report assesses Hemorrhagic Shock therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Hemorrhagic Shock
Check Discount on this report @
https://www.wiseguyreports.com/check-discount/649777-hemorrhagic-shock-pipeline-review-h2-2016
Reasons to buy
- Gain strategically significant competitor information,
analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Hemorrhagic Shock
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hemorrhagic Shock pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Hemorrhagic Shock
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hemorrhagic Shock pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Request a sample report @ https://www.wiseguyreports.com/sample-request/649777-hemorrhagic-shock-pipeline-review-h2-2016
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hemorrhagic Shock Overview 6
Therapeutics Development 7
Pipeline Products for Hemorrhagic Shock - Overview 7
Pipeline Products for Hemorrhagic Shock - Comparative Analysis 8
Hemorrhagic Shock - Therapeutics under Development by Companies 9
Hemorrhagic Shock - Therapeutics under Investigation by Universities/Institutes 10
Hemorrhagic Shock - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Hemorrhagic Shock - Products under Development by Companies 13
Hemorrhagic Shock - Products under Investigation by Universities/Institutes 14
Hemorrhagic Shock - Companies Involved in Therapeutics Development 15
Biomedica Management Corporation 15
Leading BioSciences, Inc. 16
NuvOx Pharma LLC 17
Hemorrhagic Shock - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
AM/AMBP-1 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
LB-1148 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Neutrolide - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
NVX-408 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Synthetic Peptide to Inhibit TREM-1 for Oncology, Sepsis, Rheumatoid Arthritis and Hemorrhagic Shock - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
YW-356 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Hemorrhagic Shock - Dormant Projects 35
Hemorrhagic Shock - Discontinued Products 36
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 37
Disclaimer 38
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hemorrhagic Shock Overview 6
Therapeutics Development 7
Pipeline Products for Hemorrhagic Shock - Overview 7
Pipeline Products for Hemorrhagic Shock - Comparative Analysis 8
Hemorrhagic Shock - Therapeutics under Development by Companies 9
Hemorrhagic Shock - Therapeutics under Investigation by Universities/Institutes 10
Hemorrhagic Shock - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Hemorrhagic Shock - Products under Development by Companies 13
Hemorrhagic Shock - Products under Investigation by Universities/Institutes 14
Hemorrhagic Shock - Companies Involved in Therapeutics Development 15
Biomedica Management Corporation 15
Leading BioSciences, Inc. 16
NuvOx Pharma LLC 17
Hemorrhagic Shock - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
AM/AMBP-1 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
LB-1148 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Neutrolide - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
NVX-408 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Synthetic Peptide to Inhibit TREM-1 for Oncology, Sepsis, Rheumatoid Arthritis and Hemorrhagic Shock - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
YW-356 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Hemorrhagic Shock - Dormant Projects 35
Hemorrhagic Shock - Discontinued Products 36
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 37
Disclaimer 38
Contact US:
NORAH TRENT
Partner Relations
& Marketing Manager
sales@wiseguyreports.com
Ph:
+1-646-845-9349 (US)
Ph:
+44 208 133 9349 (UK)
No comments:
Post a Comment